vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and COASTAL FINANCIAL CORP (CCB). Click either name above to swap in a different company.

COASTAL FINANCIAL CORP is the larger business by last-quarter revenue ($138.0M vs $77.6M, roughly 1.8× Bioceres Crop Solutions Corp.). On growth, COASTAL FINANCIAL CORP posted the faster year-over-year revenue change (-5.8% vs -16.8%). Over the past eight quarters, COASTAL FINANCIAL CORP's revenue compounded faster (-3.6% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Fidelity National Financial, Inc., is an American provider of title insurance and settlement services to the real estate and mortgage industries. A Fortune 500 company, Fidelity National Financial generated approximately $8.469 billion in annual revenue in 2019 from its title and real estate-related operations. The company was the first instance of an attorney licensed by a Native American Tribe being certified as "authorized house counsel" in the state of Florida.

BIOX vs CCB — Head-to-Head

Bigger by revenue
CCB
CCB
1.8× larger
CCB
$138.0M
$77.6M
BIOX
Growing faster (revenue YoY)
CCB
CCB
+11.0% gap
CCB
-5.8%
-16.8%
BIOX
Faster 2-yr revenue CAGR
CCB
CCB
Annualised
CCB
-3.6%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BIOX
BIOX
CCB
CCB
Revenue
$77.6M
$138.0M
Net Profit
$-7.4M
Gross Margin
46.8%
Operating Margin
9.3%
12.4%
Net Margin
-9.6%
Revenue YoY
-16.8%
-5.8%
Net Profit YoY
-20.2%
EPS (diluted)
$-0.12
$0.84

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
CCB
CCB
Q4 25
$138.0M
Q3 25
$77.6M
$144.7M
Q2 25
$119.4M
Q1 25
$60.6M
$139.5M
Q4 24
$98.8M
$146.5M
Q3 24
$93.3M
$151.1M
Q2 24
$135.3M
Q1 24
$84.0M
$148.4M
Net Profit
BIOX
BIOX
CCB
CCB
Q4 25
Q3 25
$-7.4M
$13.6M
Q2 25
$11.0M
Q1 25
$-1.6M
$9.7M
Q4 24
$605.2K
Q3 24
$-6.2M
$13.5M
Q2 24
$11.6M
Q1 24
$9.8M
$6.8M
Gross Margin
BIOX
BIOX
CCB
CCB
Q4 25
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
Q1 24
50.8%
Operating Margin
BIOX
BIOX
CCB
CCB
Q4 25
12.4%
Q3 25
9.3%
12.4%
Q2 25
12.0%
Q1 25
1.5%
8.4%
Q4 24
14.5%
11.7%
Q3 24
2.5%
10.8%
Q2 24
11.1%
Q1 24
15.7%
5.9%
Net Margin
BIOX
BIOX
CCB
CCB
Q4 25
Q3 25
-9.6%
9.4%
Q2 25
9.2%
Q1 25
-2.6%
7.0%
Q4 24
0.6%
Q3 24
-6.6%
8.9%
Q2 24
8.6%
Q1 24
11.6%
4.6%
EPS (diluted)
BIOX
BIOX
CCB
CCB
Q4 25
$0.84
Q3 25
$-0.12
$0.88
Q2 25
$0.71
Q1 25
$-0.02
$0.63
Q4 24
$0.00
$0.95
Q3 24
$-0.10
$0.97
Q2 24
$0.84
Q1 24
$0.14
$0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
CCB
CCB
Cash + ST InvestmentsLiquidity on hand
$15.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$288.3M
$491.0M
Total Assets
$734.9M
$4.7B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
CCB
CCB
Q4 25
Q3 25
$15.5M
Q2 25
Q1 25
$38.5M
Q4 24
$29.2M
Q3 24
$32.3M
Q2 24
Q1 24
$16.4M
Stockholders' Equity
BIOX
BIOX
CCB
CCB
Q4 25
$491.0M
Q3 25
$288.3M
$475.3M
Q2 25
$461.7M
Q1 25
$345.0M
$449.9M
Q4 24
$346.3M
$438.7M
Q3 24
$346.0M
$331.9M
Q2 24
$316.7M
Q1 24
$348.5M
$303.7M
Total Assets
BIOX
BIOX
CCB
CCB
Q4 25
$4.7B
Q3 25
$734.9M
$4.6B
Q2 25
$4.5B
Q1 25
$798.2M
$4.3B
Q4 24
$835.2M
$4.1B
Q3 24
$827.3M
$4.1B
Q2 24
$4.0B
Q1 24
$836.1M
$3.9B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
CCB
CCB
Operating Cash FlowLast quarter
$14.4M
$254.6M
Free Cash FlowOCF − Capex
$246.1M
FCF MarginFCF / Revenue
178.3%
Capex IntensityCapex / Revenue
6.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$436.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
CCB
CCB
Q4 25
$254.6M
Q3 25
$14.4M
$59.0M
Q2 25
$66.0M
Q1 25
$23.3M
$71.7M
Q4 24
$-5.4M
$259.8M
Q3 24
$5.2M
$62.6M
Q2 24
$72.1M
Q1 24
$-17.4M
$56.8M
Free Cash Flow
BIOX
BIOX
CCB
CCB
Q4 25
$246.1M
Q3 25
$57.4M
Q2 25
$64.0M
Q1 25
$68.9M
Q4 24
$249.9M
Q3 24
$60.2M
Q2 24
$69.5M
Q1 24
$55.0M
FCF Margin
BIOX
BIOX
CCB
CCB
Q4 25
178.3%
Q3 25
39.7%
Q2 25
53.6%
Q1 25
49.4%
Q4 24
170.6%
Q3 24
39.8%
Q2 24
51.3%
Q1 24
37.1%
Capex Intensity
BIOX
BIOX
CCB
CCB
Q4 25
6.1%
Q3 25
1.2%
Q2 25
1.7%
Q1 25
2.0%
Q4 24
6.8%
Q3 24
1.6%
Q2 24
1.9%
Q1 24
1.2%
Cash Conversion
BIOX
BIOX
CCB
CCB
Q4 25
Q3 25
4.34×
Q2 25
5.99×
Q1 25
7.37×
Q4 24
-8.85×
Q3 24
4.65×
Q2 24
6.22×
Q1 24
-1.78×
8.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BIOX
BIOX

Segment breakdown not available.

CCB
CCB

Other$74.7M54%
Baa S Credit Enhancements$47.3M34%
Baa S Program Income$8.4M6%
Transaction Fees$4.9M4%
Servicing And Other Baa S Fees$1.6M1%
Baa S Fraud Enhancements$1.1M1%

Related Comparisons